Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
11.15
+0.35 (3.24%)
At close: Dec 5, 2025

Mercury Biopharmaceutical Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Revenue
0.254.961.032.68--
Upgrade
Revenue Growth (YoY)
-95.72%380.44%-61.46%---
Upgrade
Cost of Revenue
0.040.780.441.51--
Upgrade
Gross Profit
0.214.180.591.17--
Upgrade
Selling, General & Admin
25.4525.5724.9116.662.480.21
Upgrade
Research & Development
47.7632.6621.3715.412.82-
Upgrade
Operating Expenses
73.2158.2346.2832.075.30.21
Upgrade
Operating Income
-73-54.04-45.69-30.9-5.3-0.21
Upgrade
Interest Expense
-0.88-0.8-0.71-0.4-0.01-
Upgrade
Interest & Investment Income
3.564.113.070.330-
Upgrade
Currency Exchange Gain (Loss)
-0.42---0.06--
Upgrade
Other Non Operating Income (Expenses)
0.210.21-0.48-0.22--
Upgrade
Pretax Income
-70.53-50.53-43.82-31.25-5.31-0.21
Upgrade
Income Tax Expense
0.060.04----
Upgrade
Net Income
-70.59-50.57-43.82-31.25-5.31-0.21
Upgrade
Net Income to Common
-70.59-50.57-43.82-31.25-5.31-0.21
Upgrade
Shares Outstanding (Basic)
423421398376277104
Upgrade
Shares Outstanding (Diluted)
423421398376277104
Upgrade
Shares Change (YoY)
4.65%5.79%5.83%36.09%165.94%-
Upgrade
EPS (Basic)
-0.17-0.12-0.11-0.08-0.02-0.00
Upgrade
EPS (Diluted)
-0.17-0.12-0.11-0.08-0.02-0.00
Upgrade
Free Cash Flow
-59.5-44.73-55.07-94.35-11.77-0.22
Upgrade
Free Cash Flow Per Share
-0.14-0.11-0.14-0.25-0.04-0.00
Upgrade
Gross Margin
84.55%84.30%57.31%43.73%--
Upgrade
Operating Margin
-29676.42%-1088.90%-4423.04%-1152.91%--
Upgrade
Profit Margin
-28696.34%-1018.90%-4241.63%-1166.05%--
Upgrade
Free Cash Flow Margin
-24186.99%-901.17%-5331.17%-3520.60%--
Upgrade
EBITDA
-64-46.59-41.62-29.15-4.73-
Upgrade
D&A For EBITDA
9.017.454.071.750.57-
Upgrade
EBIT
-73-54.04-45.69-30.9-5.3-0.21
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.